Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Claudia Baratè"'
Autor:
Sara Galimberti, Elisabetta Abruzzese, Giacomo Luci, Claudia Baratè, Luigia Luciano, Alessandra Iurlo, Giovanni Caocci, Riccardo Morganti, Fabio Stefanelli, Antonello Di Paolo
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 383 (2024)
Ponatinib may be effective in chronic myeloid leukemia (CML) patients after failure of first/second line therapies. Although its efficacy for minimum plasma concentrations (Cmin) is >21.3 ng/mL (equal to 40 nM), ponatinib may cause adverse events (AE
Externí odkaz:
https://doaj.org/article/905600479e6940c5ac0e2637b4d51945
Autor:
Massimo Breccia, Antonella Russo Rossi, Valentina Giai, Bruno Martino, Carmen Fava, Mario Annunziata, Elisabetta Abruzzese, Gianni Binotto, Claudia Baratè, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Valeria Calafiore, Maria Cristina Carraro, Federica Cattina, Francesco Cavazzini, Maria Teresa Corsetti, Lara Crucitti, Monica Crugnola, Paolo Ditonno, Ambra DI Veroli, Anna Ermacora, Felicetto Ferrara, Angelo Genua, Antonella Gozzini, Stefana Impera, Alessandra Iurlo, Luciano Levato, Luigiana Luciano, Maria Cristina Miggiano, Marco De Gobbi, Marco Santoro, Barbara Scappini, Anna Rita Scortechini, Andrea Patriarca, Serena Rosati, Sabina Russo, Rosaria Sancetta, Grazia Sanpaolo, Teresa Maria Santeramo, Silvia Sibilla, Federica Sorà, Paolo Sportoletti, Fabio Stagno, Elena Trabacchi, Fausto Castagnetti
Publikováno v:
HemaSphere, Vol 7, p e55133e1 (2023)
Externí odkaz:
https://doaj.org/article/7ea0bb7830224451ba8d9aae8fc0796c
Autor:
Anna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, Paolo Sportoletti, Alberto Fresa, Candida Vitale, Roberta Murru, Annalisa Chiarenza, Alessandro Sanna, Francesca Romana Mauro, Gianluigi Reda, Massimo Gentile, Marzia Varettoni, Claudia Baratè, Chiara Borella, Antonino Greco, Marina Deodato, Giulia Zamprogna, Roberta Laureana, Alessandra Cipiciani, Andrea Galitzia, Angelo Curto Pelle, Francesca Morelli, Lucio Malvisi, Marta Coscia, Luca Laurenti, Livio Trentin, Marco Montillo, Roberto Cairoli, Alessandra Tedeschi
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: The question of which parameters may be informative on venetoclax outcome in chronic lymphocytic leukemia (CLL) is still unclear. Furthermore, the choice to treat with venetoclax can be challenging in patients with baseline characteristic
Externí odkaz:
https://doaj.org/article/dbe82a2f5bd44711a4eb104c37135499
Autor:
Fabio Fiorino, Annalisa Ciabattini, Anna Sicuranza, Gabiria Pastore, Adele Santoni, Martina Simoncelli, Jacopo Polvere, Sara Galimberti, Claudia Baratè, Vincenzo Sammartano, Francesca Montagnani, Monica Bocchia, Donata Medaglini
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Vaccination against SARS-CoV-2 using mRNA-based vaccines has been highly recommended for fragile subjects, including myelofibrosis patients (MF). Available data on the immune responsiveness of MF patients to mRNA SARS-CoV-2 vaccination, and the impac
Externí odkaz:
https://doaj.org/article/bf5bb9c1fcca49bba08524fa4c9b1a2d
Autor:
Edoardo Benedetti, Claudia Baratè, Fabrizio Mavilia, Emilia Bramanti, Riccardo Morganti, Valentina Guerri, Giulia Cervetti, Enrico Capochiani, Ilaria Bertaggia, Salvatore Massimo Stella, Ginevra Traverso, Benedetto Bruno, Sara Galimberti
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 5, p 1772 (2023)
A fixed duration of venetoclax-rituximab (VenR) resulted in a significant benefit of both PFS and in the attainment of an undetectable minimal residual disease (uMRD) compared with bendamustine-rituximab in relapsed/refractory (R/R) chronic lymphocyt
Externí odkaz:
https://doaj.org/article/eba91b31343a4729b604be8b0f17afdb
Autor:
Monica Carpenedo, Erminia Baldacci, Claudia Baratè, Alessandra Borchiellini, Francesco Buccisano, Giuseppina Calvaruso, Federico Chiurazzi, Bruno Fattizzo, Gaetano Giuffrida, Elena Rossi, Francesca Palandri, Potito Rosario Scalzulli, Sergio Mario Siragusa, Angelantonio Vitucci, Francesco Zaja
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Introduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agon
Externí odkaz:
https://doaj.org/article/f778d6c8959641f2847bc57d4ee14356
Autor:
Edoardo Benedetti, Fabrizio Mavilia, Claudia Baratè, Emilia Bramanti, Riccardo Morganti, Giulia Cervetti, Enrico Capochiani, Benedetto Bruno, Matteo Pelosini, Salvatore Massimo Stella, Sara Galimberti
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 11, p 3206 (2022)
Background. In IWCLL guidelines, progressive splenomegaly and lymphadenopathy are signs of active disease. In this study, we have tested the hypotheses if US could be a reliable tool for both superficial lymphnodes (SupLNs) and splenic assessment in
Externí odkaz:
https://doaj.org/article/f33ab23459f64793afe1f96cf4ac8488
Autor:
Sara Galimberti, Mario Petrini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, Francesca Guerrini, Elena Ciabatti, Sandra Mechelli, Antonello Di Paolo, Chiara Baldini, Laura Baglietto, Lisa Macera, Pietro Giorgio Spezia, Fabrizio Maggi
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective
Externí odkaz:
https://doaj.org/article/008940af48964fb69bb44c865433b1e1
Autor:
Federica Ricci, Serena Balducci, Francesca Guerrini, Susanna Grassi, Elena Ciabatti, Claudia Baratè, Maria Immacolata Ferreri, Cecilia Giuliani, Angelo Valetto, Mario Petrini, Sara Galimberti
Publikováno v:
Clinical Hematology International, Vol 2, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/4e73241241fb4fafa6a98e133a4f50a2
Autor:
Elena Maria Elli, Claudia Baratè, Francesco Mendicino, Francesca Palandri, Giuseppe Alberto Palumbo
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The JAK-STAT signaling pathway plays a central role in signal transduction in hematopoietic cells, as well as in cells of the immune system. The occurrence in most patients affected by myeloproliferative neoplasms (MPNs) of driver mutations resulting
Externí odkaz:
https://doaj.org/article/094fbf28662f45a4b296bbc1611bb41d